Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 1;106(1):269-274.
doi: 10.3324/haematol.2019.227371.

Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation

Rima M Saliba  1 , Lauren Veltri  2 , Gabriela Rondon  1 , Julianne Chen  1 , Gheath Al-Atrash  1 , Amin Alousi  1 , Charles Martinez  1 , LaJerald Augustine  1 , Chitra M Hosing  1 , Betul Oran  1 , Katayoun Rezvani  1 , Elisabeth J Shpall  1 , Partow Kebriaei  1 , Issa F Khouri  1 , Uday Popat  1 , Richard E Champlin  1 , Stefan O Ciurea  1
Affiliations

Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation

Rima M Saliba et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Distributions of CD4+ and CD8+ cell percentages and risk stratifications based on graft, donor and recipient-characteristics. (A) The distributions of %CD4+ and %CD8+ cells in unmanipulated bone marrow grafts vary according to CD4+/CD8+ cell ratio (CD4/CD8). Distributions of %CD4+ and %CD8+ cells are skewed in low (≤0.85) and high (>1.5) CD4/CD8 quartiles. CD8+ cells are predominant in grafts with a CD4/CD8 ≤0.85 and CD4+ cells are predominant in grafts with a CD4/CD8 >1.5. Data are illustrated in a box-and-whisker plot with the whiskers indicating the 25th and 75th percentiles. Lines within the box plots indicate the median %CD4+ and %CD8+ cells in each CD4/CD8 quartile. (B-F) Results of multivariate classification and regression tree (CART) analysis are shown for severe acute graft-versus-host disease (B), early non-relapse mortality (C), late non-relapse mortality (D), disease progression (E), and progression-free survival (F). Two figures are presented for each outcome depicting the risk classification algorithm (left figure) generated by CART analysis, and the corresponding cumulative incidence curves (right figure) for each subgroup represented in the risk stratification algorithm. N: number; aGVHD: acute graft-versus-host disease; %CI: percent cumulative incidence; NRM: non-relapse mortality; HCT-CI: Hematopoietic Cell Transplantation - Comorbidity Index; CMV: cytomegalovirus serostatus; DRI: Disease Risk Index; prg: progressive disease; TNC: total nucleated cells; PFS: progression-free survival.
See this image and copyright information in PMC

References

    1. Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015; 126(8):1033-1040. - PMC - PubMed
    1. Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. Reducedintensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127(7):938-947. - PMC - PubMed
    1. Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLAmatched related and unrelated donor transplantation. J Clin Oncol. 2013; 31(10):1310-1316. - PubMed
    1. Gaballa S, Ge I, El Fakih R, et al. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016;122(21):3316-3326. - PMC - PubMed
    1. Luo XH, Chang YJ, Xu LP, Liu DH, Liu KY, Huang XJ. The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT. Bone Marrow Transplant. 2009;43(1):29-36. - PubMed

Publication types

Substances